482 related articles for article (PubMed ID: 32370750)
1. Oncolytic Newcastle disease virus delivered by Mesenchymal stem cells-engineered system enhances the therapeutic effects altering tumor microenvironment.
Keshavarz M; Ebrahimzadeh MS; Miri SM; Dianat-Moghadam H; Ghorbanhosseini SS; Mohebbi SR; Keyvani H; Ghaemi A
Virol J; 2020 May; 17(1):64. PubMed ID: 32370750
[TBL] [Abstract][Full Text] [Related]
2. Mesenchymal stem cells enhance the oncolytic effect of Newcastle disease virus in glioma cells and glioma stem cells via the secretion of TRAIL.
Kazimirsky G; Jiang W; Slavin S; Ziv-Av A; Brodie C
Stem Cell Res Ther; 2016 Oct; 7(1):149. PubMed ID: 27724977
[TBL] [Abstract][Full Text] [Related]
3. Combination immunotherapy using G-CSF and oncolytic virotherapy reduces tumor growth in osteosarcoma.
Morales-Molina A; Gambera S; Leo A; García-Castro J
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33737338
[TBL] [Abstract][Full Text] [Related]
4. Recombinant oncolytic Newcastle disease virus displays antitumor activities in anaplastic thyroid cancer cells.
Jiang K; Song C; Kong L; Hu L; Lin G; Ye T; Yao G; Wang Y; Chen H; Cheng W; Barr MP; Liu Q; Zhang G; Ding C; Meng S
BMC Cancer; 2018 Jul; 18(1):746. PubMed ID: 30021550
[TBL] [Abstract][Full Text] [Related]
5. Genetically engineered Newcastle disease virus expressing interleukin-2 and TNF-related apoptosis-inducing ligand for cancer therapy.
Bai FL; Yu YH; Tian H; Ren GP; Wang H; Zhou B; Han XH; Yu QZ; Li DS
Cancer Biol Ther; 2014 Sep; 15(9):1226-38. PubMed ID: 24971746
[TBL] [Abstract][Full Text] [Related]
6. Engineering Newcastle Disease Virus as an Oncolytic Vector for Intratumoral Delivery of Immune Checkpoint Inhibitors and Immunocytokines.
Vijayakumar G; McCroskery S; Palese P
J Virol; 2020 Jan; 94(3):. PubMed ID: 31694938
[TBL] [Abstract][Full Text] [Related]
7. Newcastle disease virotherapy induces long-term survival and tumor-specific immune memory in orthotopic glioma through the induction of immunogenic cell death.
Koks CA; Garg AD; Ehrhardt M; Riva M; Vandenberk L; Boon L; De Vleeschouwer S; Agostinis P; Graf N; Van Gool SW
Int J Cancer; 2015 Mar; 136(5):E313-25. PubMed ID: 25208916
[TBL] [Abstract][Full Text] [Related]
8. Oncolytic Newcastle disease virus activation of the innate immune response and priming of antitumor adaptive responses in vitro.
Burke S; Shergold A; Elder MJ; Whitworth J; Cheng X; Jin H; Wilkinson RW; Harper J; Carroll DK
Cancer Immunol Immunother; 2020 Jun; 69(6):1015-1027. PubMed ID: 32088771
[TBL] [Abstract][Full Text] [Related]
9. Newcastle disease virus: a promising agent for tumour immunotherapy.
Zhao L; Liu H
Clin Exp Pharmacol Physiol; 2012 Aug; 39(8):725-30. PubMed ID: 22211810
[TBL] [Abstract][Full Text] [Related]
10. Counteracting Immunosuppression in the Tumor Microenvironment by Oncolytic Newcastle Disease Virus and Cellular Immunotherapy.
Schirrmacher V; van Gool S; Stuecker W
Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36361831
[TBL] [Abstract][Full Text] [Related]
11. A comparative study of neural and mesenchymal stem cell-based carriers for oncolytic adenovirus in a model of malignant glioma.
Ahmed AU; Tyler MA; Thaci B; Alexiades NG; Han Y; Ulasov IV; Lesniak MS
Mol Pharm; 2011 Oct; 8(5):1559-72. PubMed ID: 21718006
[TBL] [Abstract][Full Text] [Related]
12. Newcastle disease virus as an oncolytic agent.
Ravindra PV; Tiwari AK; Sharma B; Chauhan RS
Indian J Med Res; 2009 Nov; 130(5):507-13. PubMed ID: 20090097
[TBL] [Abstract][Full Text] [Related]
13. Targeting aerobic glycolysis by dichloroacetate improves Newcastle disease virus-mediated viro-immunotherapy in hepatocellular carcinoma.
Meng G; Li B; Chen A; Zheng M; Xu T; Zhang H; Dong J; Wu J; Yu D; Wei J
Br J Cancer; 2020 Jan; 122(1):111-120. PubMed ID: 31819179
[TBL] [Abstract][Full Text] [Related]
14. Mesenchymal stem cells loaded with oncolytic reovirus enhances antitumor activity in mice models of colorectal cancer.
Babaei A; Soleimanjahi H; Soleimani M; Arefian E
Biochem Pharmacol; 2021 Aug; 190():114644. PubMed ID: 34090878
[TBL] [Abstract][Full Text] [Related]
15. Combined therapy of oncolytic Newcastle disease virus and rhizomes extract of Rheum ribes enhances cancer virotherapy in vitro and in vivo.
Al-Shammari AM; Jalill RDA; Hussein MF
Mol Biol Rep; 2020 Mar; 47(3):1691-1702. PubMed ID: 31970625
[TBL] [Abstract][Full Text] [Related]
16. Oncolytic Newcastle disease virus effects on immune response - a new issue in cancer treatment.
Kooti W; Esmaeili HGG; Farzanehpour M; Dorostkar R; Jalali Kondori B; Bolandian M
Klin Onkol; 2023; 36(2):124-129. PubMed ID: 37072246
[TBL] [Abstract][Full Text] [Related]
17. Intratumoral Virotherapy with Wild-Type Newcastle Disease Virus in Carcinoma Krebs-2 Cancer Model.
Yurchenko KS; Glushchenko AV; Gulyaeva MA; Bi Y; Chen J; Shi W; Adamenko LS; Shestopalov AM
Viruses; 2021 Mar; 13(4):. PubMed ID: 33806229
[TBL] [Abstract][Full Text] [Related]
18. Oncolytic Newcastle disease virus for cancer therapy: old challenges and new directions.
Zamarin D; Palese P
Future Microbiol; 2012 Mar; 7(3):347-67. PubMed ID: 22393889
[TBL] [Abstract][Full Text] [Related]
19. [Progress in using Newcastle disease virus for tumor therapy: a review].
Wu Y; Hao J; Li D
Sheng Wu Gong Cheng Xue Bao; 2010 Aug; 26(8):1031-6. PubMed ID: 21090105
[TBL] [Abstract][Full Text] [Related]
20. Mesenchymal stem cells used as carrier cells of oncolytic adenovirus results in enhanced oncolytic virotherapy.
Mahasa KJ; de Pillis L; Ouifki R; Eladdadi A; Maini P; Yoon AR; Yun CO
Sci Rep; 2020 Jan; 10(1):425. PubMed ID: 31949228
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
